aHUS Trial Watch 15 ( Iptacopan) update

Global Action featured a new trial for an aHUS treatment iptacopan earlier this year ( CLICK ON IMAGE BELOW)

aHUS Trial Watch 15 (Iptacopan)

aHUS Trial Watch 15 (Iptacopan)

Iptacopan is a complement inhibitor that it is taken orally, twice daily. It works by inhibiting Complement Factor B (CFB ). Without CFB , C5 cannot be activated to create…CONTINUE READING

At that time only three investigation sites were recruiting. That number has been increased with sites in seven other counties including the USA ( Los Angeles and Albuqueque) . Also sites in Brazil, South Korea and Taiwan and most noticeably India.

See all the current recruiting sites listed below.

Iptacopan is an oral medicine taken twice a day to inhibit Complement.

United States, California
Novartis Investigative SiteRecruiting
Torrance, California, United States, 90502
United States, New Mexico
Novartis Investigative SiteRecruiting
Albuquerque, New Mexico, United States, 87131
Austria
Novartis Investigative SiteRecruiting
Innsbruck, Tyrol, Austria, 6020
Novartis Investigative SiteRecruiting
Wien, Austria, 1090
Brazil
Novartis Investigative SiteRecruiting
Sao Paulo, SP, Brazil, 05403 000
Novartis Investigative SiteRecruiting
São Paulo, SP, Brazil, 04038-002
Czechia
Novartis Investigative SiteRecruiting
Praha 4, Czechia, 140 00
Greece
Novartis Investigative SiteRecruiting
Thessaloniki, GR, Greece, 570 10
India
Novartis Investigative SiteRecruiting
Vellore, Tamil Nadu, India, 632004
Japan
Novartis Investigative SiteRecruiting
Iruma-gun, Saitama, Japan, 350-0495
Novartis Investigative SiteRecruiting
Izumo-city, Shimane, Japan, 693 8501
Korea, Republic of
Novartis Investigative SiteRecruiting
Seoul, Korea, Republic of, 03080
Novartis Investigative SiteRecruiting
Seoul, Korea, Republic of, 03722
Slovenia
Novartis Investigative SiteRecruiting
Ljubljana, Slovenia, 1000
Taiwan
Novartis Investigative SiteRecruiting
Taichung, Taiwan, 40447
Novartis Investigative SiteRecruiting
Taoyuan, Taiwan, 33305

Article No. 524

Leave a Reply